Cancer

Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial

Pathology data indicate 70% overall response rate for squamous cell carcinomas: 100% clearance in 10 out of 14 responders Favorable...

BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)

Study subject Remains in Complete Response for 3 YearsExceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent...

Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection

BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF

VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience...

Digital Pathology Market Growing at 9.9% CAGR to 2031 as AI Adoption Accelerates, says a 2026 Mordor Intelligence Report

HYDERABAD, India, Jan. 16, 2026 /PRNewswire/ -- According to Mordor Intelligence, the digital pathology market is valued at USD 2.01 billion in 2026, and is projected...

Children’s Brain Tumor Network to Empower National Expansion of Pediatric Data Sharing Through ARPA-H Pediatric Care eXpansion (PCX)

CBTN will help scale real-time, interoperable data across more than 200 hospitals nationwide.PHILADELPHIA, Jan. 15, 2026 /PRNewswire/ -- The Children's...

Children’s Brain Tumor Network to Empower National Expansion of Pediatric Data Sharing Through ARPA-H Pediatric Care eXpansion (PCX)

CBTN will help scale real-time, interoperable data across more than 200 hospitals nationwide.PHILADELPHIA, Jan. 15, 2026 /PRNewswire/ -- The Children's...

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately...

error: Content is protected !!